Get the Stockscreener App
19.51
1.76%
-0.35
After Hours:
19.51
Castle Biosciences Inc stock is currently priced at $19.51, with a 24-hour trading volume of 180.32K.
It has seen a -1.76% decreased in the last 24 hours and a -6.29% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $19.88 pivot point. If it approaches the $19.47 support level, significant changes may occur.
Previous Close:
$19.86
Open:
$19.07
24h Volume:
180.32K
Market Cap:
$538.22M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-5.8239
EPS:
-3.35
Net Cash Flow:
$-19.25M
1W Performance:
+1.61%
1M Performance:
-6.29%
6M Performance:
+54.11%
1Y Performance:
-13.67%
1D Range:
$18.76
$19.70
52W Range:
$9.2601
$26.48
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
602-535-1997
Address
820 South Friendswood Drive, Suite 201, Friendswood, TX
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics
Zacks Investment Research
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
Zacks Investment Research
Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky
MarketWatch
Castle Biosciences Inc Stock (CSTL) Financials Data
Castle Biosciences Inc (CSTL) Revenue 2024
CSTL reported a revenue (TTM) of $219.79 million for the quarter ending December 31, 2023, a +60.38% rise year-over-year.
Castle Biosciences Inc (CSTL) Net Income 2024
CSTL net income (TTM) was -$57.47 million for the quarter ending December 31, 2023, a +14.41% increase year-over-year.
Castle Biosciences Inc (CSTL) Cash Flow 2024
CSTL recorded a free cash flow (TTM) of -$19.25 million for the quarter ending December 31, 2023, a +59.30% increase year-over-year.
Castle Biosciences Inc (CSTL) Earnings per Share 2024
CSTL earnings per share (TTM) was -$2.15 for the quarter ending December 31, 2023, a +16.67% growth year-over-year.
About Castle Biosciences Inc
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
4.61%
Cap:
|
Volume (24h):